Viatris Inc. (NASDAQ:VTRS) has been recognized as one of the 13 Best March Dividend Stocks to Buy. UBS recently raised its price target on Viatris to $20 from $18, maintaining a Buy rating on the stock. The firm highlighted Viatris meeting its Q4 cost-saving goals and issuing FY26 guidance above consensus expectations. Despite this positive news, the shares dropped 5% following earlier gains in the year.
The upcoming March 19 investor event is anticipated to be significant, potentially outlining a path towards mid-single-digit revenue growth. UBS also mentioned ongoing cost reductions supporting a teen-level EPS compound annual growth rate, which could drive meaningful multiple expansion over time.
CEO Scott Smith reported Viatris’ Q4 2025 results, noting a strong year with total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion. Smith emphasized progress in the company’s pipeline, highlighting positive results from five Phase III studies and ongoing enrollment in key programs like cenerimod and selatogrel.
Viatris returned over $1 billion to shareholders through dividends and share repurchases in 2025. The completion of 60 regional transactions, including the acquisition of Aculys Pharma in Japan, aligns with the company’s strategic plan.
Looking ahead, Viatris expects to generate approximately $650 million in gross cost savings over three years, with up to $250 million reinvested into growth initiatives. The company has also prepared for a potential FDA reinspection of its Indore facility, implementing operational redundancies to ensure continuity and stability.
Viatris operates as a global healthcare company with business operations in Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment includes primary operations in North America and Europe.
While Viatris shows promise as an investment, some AI stocks may offer greater upside potential and lower downside risk. For those interested in an undervalued AI stock poised to benefit from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock is available.
In conclusion, Viatris continues to demonstrate financial strength and strategic growth initiatives that position the company for sustainable long-term success. Investors should monitor upcoming developments, such as the March 19 investor event, to gain insights into Viatris’ future growth trajectory.
